<?xml version="1.0" encoding="UTF-8"?>
<p>Dysregulation of CDKs-cyclin pathway resulting in uncontrolled proliferation have been observed in various cancers
 <xref rid="CIT0020" ref-type="bibr">
  <sup>20–22</sup>
 </xref>. Owing to the important role of CDKs in the control of cell division, numerous drugs targeting CDKs were designed and reported in the clinic
 <xref rid="CIT0023" ref-type="bibr">
  <sup>23</sup>
 </xref>. Several selective CDK4/6 inhibitors have been reported in the recent years. Pfizer’s palbociclib represents the first CDK inhibitor approved by the US FDA in February 2015 to treat HR+/HER2-breast cancer
 <xref rid="CIT0024" ref-type="bibr">
  <sup>24</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0025" ref-type="bibr">
  <sup>25</sup>
 </xref>. Novartis’ ribociclib and Lilly’s abemaciclib also got a fast approval by FDA in March 2017 and September 2017, respectively, to treat HR+/HER2-breast cancer
 <xref rid="CIT0026" ref-type="bibr">
  <sup>26</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0027" ref-type="bibr">
  <sup>27</sup>
 </xref>. While as reported, both palbociclib and ribociclib as selective CDK4/6 inhibitors need to combine with letrozole for the treatment of breast cancer
 <xref rid="CIT0028" ref-type="bibr">
  <sup>28</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0029" ref-type="bibr">
  <sup>29</sup>
 </xref>. Abemaciclib with additional kinase activities, such as CDK1, CDK2 and CDK9 shows unique single-agent activities
 <xref rid="CIT0030" ref-type="bibr">
  <sup>30</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0031" ref-type="bibr">
  <sup>31</sup>
 </xref>. These studies indicate that monotherapy targeting of individual cell cycle CDKs may be insufficient for cancer therapy.
</p>
